US 11,883,413 B2
Inhibition of thymine DNA glycosylase in the treatment of cancer
Alfonso Bellacosa, Philadelphia, PA (US); Rossella Tricarico, Philadelphia, PA (US); Tim Yen, Philadelphia, PA (US); Vikram Bhattacharjee, Philadelphia, PA (US); Pietro Mancuso, Philadelphia, PA (US); Lionel Larue, Paris (FR); and Irwin Davidson, Ilkrich (FR)
Filed by Institute For Cancer Research, Philadelphia, PA (US); Institut Curie, Paris (FR); and Institut de Genetique et de Biologie Moleculaire et Cellulaire, Illkrich (FR)
Filed on Jun. 25, 2021, as Appl. No. 17/358,852.
Application 17/358,852 is a continuation of application No. 15/084,680, filed on Mar. 30, 2016, granted, now 11,077,121.
Application 15/084,680 is a continuation of application No. PCT/US2014/058240, filed on Sep. 30, 2014.
Claims priority of provisional application 61/884,478, filed on Sep. 30, 2013.
Prior Publication US 2022/0054500 A1, Feb. 24, 2022
Int. Cl. A61K 31/5575 (2006.01); A61K 31/122 (2006.01); A61K 31/277 (2006.01); A61K 31/475 (2006.01); A61K 31/495 (2006.01); A61K 31/546 (2006.01); A61P 35/00 (2006.01); A61K 31/609 (2006.01); A61K 31/473 (2006.01); A61K 31/404 (2006.01); A61K 31/353 (2006.01); A61K 33/243 (2019.01); A61K 33/24 (2019.01)
CPC A61K 31/5575 (2013.01) [A61K 31/122 (2013.01); A61K 31/277 (2013.01); A61K 31/353 (2013.01); A61K 31/404 (2013.01); A61K 31/473 (2013.01); A61K 31/475 (2013.01); A61K 31/495 (2013.01); A61K 31/546 (2013.01); A61K 31/609 (2013.01); A61K 33/24 (2013.01); A61K 33/243 (2019.01); A61P 35/00 (2018.01); C12N 2740/15043 (2013.01)] 7 Claims
 
1. A method of treating cancer in a patient in need thereof, the method comprising administering to the patient an inhibitor of thymine DNA glycosylase (TDG) in an amount effective to inhibit TDG in cancer cells, wherein the cancer is melanoma, prostate cancer, pancreatic cancer, breast cancer, colon cancer, lung cancer, or glioblastoma, and wherein the inhibitor of TDG is selected from the group consisting of hexadimethrine bromide, indigotindisulfonate, and protamine chloride.